NICE says yes and no to Amgen's Xgeva
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, maintains that Amgen's Xgeva (denosumab) would not be cost-effective for preventing skeletal-related events in adults with bone metastases from prostate cancer on the National Health Service. However, according to today's final appraisal determination, it still looks set to recommend the drug for preventing SREs in other patients.
You may also be interested in...
Voluntary EU Joint Clinical Assessments ‘Risk Access To Medicines’
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Future Unclear For EU Mandatory Joint Clinical Assessment Plans
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: